These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 31005596)
1. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. Zebala JA; Searle SL; Webster LR; Johnson MS; Schuler AD; Maeda DY; Kahn SJ J Pain; 2019 Oct; 20(10):1218-1235. PubMed ID: 31005596 [TBL] [Abstract][Full Text] [Related]
2. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095 [TBL] [Abstract][Full Text] [Related]
4. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Pedersen RS; Damkier P; Brosen K Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977 [TBL] [Abstract][Full Text] [Related]
5. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820 [TBL] [Abstract][Full Text] [Related]
6. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Fliegert F; Kurth B; Göhler K Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019 [TBL] [Abstract][Full Text] [Related]
7. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051 [TBL] [Abstract][Full Text] [Related]
9. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346 [TBL] [Abstract][Full Text] [Related]
10. The hypoalgesic effect of tramadol in relation to CYP2D6. Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065 [TBL] [Abstract][Full Text] [Related]
11. Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. Nielsen AG; Pedersen RS; Noehr-Jensen L; Damkier P; Brosen K Eur J Clin Pharmacol; 2010 Jul; 66(7):655-60. PubMed ID: 20354688 [TBL] [Abstract][Full Text] [Related]
12. Oral Coadministration of Fluconazole with Tramadol Markedly Increases Plasma and Urine Concentrations of Tramadol and the Perez Jimenez TE; Kukanich B; Joo H; Mealey KL; Grubb TL; Greene SA; Court MH Drug Metab Dispos; 2019 Jan; 47(1):15-25. PubMed ID: 30366901 [TBL] [Abstract][Full Text] [Related]
13. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of tramadol and Lee J; Yoo HD; Bae JW; Lee S; Shin KH Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765 [No Abstract] [Full Text] [Related]
15. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. Miotto K; Cho AK; Khalil MA; Blanco K; Sasaki JD; Rawson R Anesth Analg; 2017 Jan; 124(1):44-51. PubMed ID: 27861439 [TBL] [Abstract][Full Text] [Related]
16. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients. Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214 [TBL] [Abstract][Full Text] [Related]
17. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. de Moraes NV; Lauretti GR; Lanchote VL J Pharm Pharmacol; 2014 Sep; 66(9):1222-30. PubMed ID: 24717054 [TBL] [Abstract][Full Text] [Related]
18. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Brosen K Clin Pharmacol Ther; 2009 Dec; 86(6):626-33. PubMed ID: 19710642 [TBL] [Abstract][Full Text] [Related]
19. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate. Srinivas NR J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475 [TBL] [Abstract][Full Text] [Related]
20. Miotic action of tramadol is determined by CYP2D6 genotype. Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]